Clinical Trials
3 trialsNCT01564914 2019-06-12
105GM201
Tracon Pharmaceuticals Inc.
Phase 2 Completed
NCT01648348 2018-05-23
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01778530 2015-10-07
TRC105 for Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated